FDA Downgrades Opioid Oxygen Monitor to Class II
Published Date: 6/30/2026
Rule
Summary
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Class II Reclassification Speeds Access
FDA has classified the monitor for opioid-induced impairment of oxygenation as Class II (special controls). This final order is effective June 30, 2026 (and the classification was applicable on March 31, 2023), and FDA says the change provides reasonable assurance of safety and effectiveness while enhancing patients' access by reducing regulatory burdens.
Easier Route to Market for Makers
Because FDA placed this monitor into Class II via the De Novo process, the device can serve as a predicate for future devices so other sponsors can use the less burdensome 510(k) pathway instead of De Novo or premarket approval. FDA states this will enhance patient access in part by reducing regulatory burdens and could lower costs and delays for companies making these monitors.
Special Controls Require Testing and Documentation
Manufacturers of these monitors must meet detailed special controls, including clinical performance data (accuracy, sensitivity, specificity), software verification and validation with hazard analysis, non-clinical sensor performance testing, usability assessment, biocompatibility, and electromagnetic and safety testing. Compliance with these special controls is required for the device to remain in Class II and avoid automatic placement in Class III.
Labels Must Include Overdose Warnings and Info
Labeling for these monitors must include a summary of clinical validation (including sensitivity, specificity, positive and negative predictive values by subpopulation), principles of sensor operation, information on preventing, recognizing, and treating an overdose, warnings that the device may not distinguish other conditions, warnings against overreliance, and a warning about the need for supervised use with awareness of countermeasures such as naloxone.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13139 — Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-13101 — Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Absorber
The FDA is officially classifying the medial knee implanted shock absorber as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative knee device faster and with confidence in its safety. The new classification is effective June 29, 2026, and could save time and money for makers and users alike.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
2026-12937 — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
The FDA is giving folks more time to share their thoughts on whether certain medicines like semaglutide, tirzepatide, and liraglutide should be allowed for special compounding by outsourcing drug makers. This extension means anyone interested has until July 30, 2026, to weigh in. It affects drug makers, healthcare pros, and patients waiting for these meds, with no immediate cost changes but plenty of chances to influence future drug availability.
Previous / Next Documents
Previous: 2026-13139 — Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
Next: 2026-13153 — Magnuson-Stevens Fishery Conservation and Management Act Provisions; Fisheries of the Northeastern United States; Northeast Multispecies Fishery; Amendment 25 (Revised)
Starting June 30, 2026, new rules update how Atlantic cod stocks are managed in the Northeast multispecies fishery. These changes affect both commercial and recreational fishers by setting fresh limits and protections to stop overfishing and help cod populations bounce back. The goal? Keep fishing fun and sustainable while supporting a $40 million industry.